📢 En 2024, Gustave Roussy obtenait la 4e place au niveau mondial dans le classement Newsweek des ✨Best specialized hospitals in oncology✨.

🗳️ Etre invité au prochain cycle de l'enquête par les pairs via le lien suivant : survey.statista-research.com/481811?lang=en.

The kick-off Meeting of the Prism Center IHU-A will be on Thursday May 2nd. It’s an opportunity to organise a nice seminar around Precision Medicine w Vivek Subbiah, MD & Nicholas McGranahan as speakers. you are welcome to join us (+ there is a cocktail at the end 🥂🧉🍹🥤🧃🍵☕️ !)

Celebrating the 10th anniversary of the PEACE consortium, a European Prostate Cancer Research Group. 10 years, 10 phase III randomized trials… huge impact on patients, led by Prof Karim Fizazi. Congrats! #APCCC24

Fernanda Mosele And so pround and lucky to work with a dream team UNLOCK-ICARUS to better understand new drugs to improve the outcome of patients with cancer ylt Fernanda Mosele Julieta Rodriguez FabriceAndre Barbara Pistilli Gustave Roussy

📰 Les chercheurs de Gustave Roussy accueillis par Dana-Farber🤝

Naoual Menssouri, François-Xavier Danlos, Damien Vasseur et Thomas Grinda : bravo pour votre engagement ! 💪👏

And that is a wrap for the Transatlantic conference between Dana-Farber Gustave Roussy around the topic of “liquid biopsies”—thank you to all the faculty, @medscape + Servier

See you next year in Paris !
#

Launch of the Third Transatlantic exchange in Oncology in Boston. 🇺🇸

Dana-Farber and Gustave Roussy are proud to share their progress in #cancer treatment.

🎯 This third edition will be dedicated to Liquid biopsy as en emerging approach in precision cancer medicine.

Outstanding comprehensive talk from Benjamin Besse about applications of MRD in lung cancer during the transatlantic exchanges conference

Dana-Farber Gustave Roussy

Outstanding comprehensive talk from ⁦ylt⁩ about applications of MRD in GU cancers during the transatlantic exchanges conference between ⁦Dana-Farber⁩ ⁦Gustave Roussy⁩

Eagerly awaiting data from CM-274 at #EAU24 Adjuvant NIVOLUMAB showing improved OS in ITT and PD-L1 ≥1% urothelial cancers 🌟🌟🌟
#EAU24 #Oncology
Matt Galsky Tom Powles OncoAlert
Niklas Klümper Uromigos

The 3rd Transatlantic Exchange between Dana-Farber & Gustave Roussy in Oncology Conference is coming up with the topic of' Liquid Biopsy as an Emerging Approach in Precision Cancer Medicine'

APRIL 12, 2024 | 8:00 AM - 4:15 PM ET (in-person in Boston and Virtual)

LINK:…

📰 Accord de recherche entre Gustave Roussy et Amgen France pour prédire l’efficacité des anticorps conjugués.

Lire le communiqué de presse ⤵ gustaveroussy.fr/fr/accord-de-r…

In Annals of Oncology, the ESMO - Eur. Oncology Clinical Practice Guideline interim update on 1st-line therapy in advanced urothelial carcinoma following the results of the EV-302/KEYNOTE-A39 randomized phase 3 trial initially presented by Tom Powles at #ESMO23
annalsofoncology.org/article/S0923-…

Updated #BladderCancer #ESMOGuideline 📢 A change to the SoC for 1st line therapy for 1st time in 40 years. Enfortumab vedotin + pembro (EVP) new SoC in 1st-line advanced #UrothelialCarcinoma . Nivolumab–cisplatin–gemcitabine or platinum ChT & maintenance avelumab alternatives if…

🎯Practice changing👉EV-302 just published in NEJM for 1st line metastatic urothelial cancer👇
nejm.org/doi/full/10.10…
1️⃣ OS 👉 Enfortumab vedotin-Pembro 31.5 months vs. 16.1 months chemo
2️⃣ PFS 👉12.5 months EV-P vs. 6.3 months chemo.
3️⃣ ORR 👉EV-P 67.7% vs. chemo 44.4%…

In a new Review now live online, Katoh et al. discuss the clinical activity, mechanisms of resistance and new directions of FGFR-targeted therapeutics: nature.com/articles/s4157…

Sacituzumab + Pembro is efficacious in metastic urothelial cancer following progress on platinum based chemotherapy !! Very interesting study by Petros Grivas and ylt and team that unfortunately comes late. Is there still a place for this regimen after EV302 results ?
But…

Sacituzumab Govitecan + Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3 | Journal of Clinical Oncology Petros Grivas Neeraj Agarwal, MD, FASCO ylt ascopubs.org/doi/10.1200/JC…

From MATCH-R to UNLOCK: to decipher mechanism of action and resistance of new drugs @ylt ⁦FabriceAndre⁩ ⁦Gustave Roussy⁩

Metastatic cancers should be classified as much as possible based on their biology, and agnostic of organ of origin
To reach this vision, new statistical tools are needed to claim that drugs work across multiple cancers
TY nature & Lucy Odling-Smee for the opportunity to write about it